Current Report Filing (8-k)
November 05 2020 - 6:59AM
Edgar (US Regulatory)
0001023024
false
0001023024
2020-11-05
2020-11-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): November 5, 2020
ANI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-31812
|
58-2301143
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification Number)
|
210 Main Street West
Baudette, Minnesota
|
|
56623
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including
area code: (218) 634-3500
(Former name or former
address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class:
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered:
|
Common Stock
|
|
ANIP
|
|
Nasdaq Stock Market
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this
chapter).
Emerging growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02
|
|
Results of Operations and Financial Condition.
|
On November 5, 2020, ANI
Pharmaceuticals, Inc. (“ANI”) issued a press release announcing its financial and operating results for the three
and nine months ended September 30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this report.
In accordance with General
Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall
not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference
into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such filing.
Item 9.01
|
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ANI PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Stephen P. Carey
|
|
|
Stephen P. Carey
|
|
|
Vice President, Finance and Chief Financial Officer
|
Dated: November 5, 2020
|
|
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Mar 2024 to Apr 2024
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Apr 2023 to Apr 2024